Video

Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBC

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer (TNBC).

The randomized trial assessed the effect of adding carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy on long-term patient outcomes. The study population consisted of 720 patients who were randomly assigned 1:1 to the experimental vs control regimens. These patients were stratified according to menopausal status and tumor stage. After completing the study regimen, patients proceeded to surgery followed by radiotherapy.

The study’s primary end point was event-free survival (EFS) followed by overall survival (OS) as a secondary end point, Gupta begins. Results demonstrated an absolute increase in both EFS and OS with weekly carboplatin plus paclitaxel, he states. EFS increased by 6.6 percentage points in the total population, and by 12.5% in patients under 50 years of age. Subgroup analyses found that both OS and EFS benefits with carboplatin were limited to young, premenopausal patients, Gupta notes. This finding indicates that there is a significant interaction between treatment and age thatrequires further investigation.

Safety data showed an increased risk of hematological toxicities with the addition of carboplatin, consistent with previous expectations, Gupta continues. However, this increase did not result in treatment discontinuation for most patients in both arms. Regarding compliance to neoadjuvant chemotherapy in the experimental arm, 94.5% and 77.6% of patients completed 8 and 12 treatment cycles, respectively. Conversely, 97.2% and 80.1% of patients in the control arm completed 8 and 12 treatment cycles. Accordingly, carboplatin plus neoadjuvant chemotherapy was considered well tolerated in this patient population, Gupta says. 

Overall, neoadjuvant platinum therapy not only produces a clinically meaningful survival benefit in young patients but should be considered a new standard-of-care component for this patient subset, Gupta concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

May 15th 2025 - May 16th 2026

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer
Video

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

May 15th 2025 - May 16th 2026

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Louisiana

May 14th 2025 - Jun 19th 2025

online-activity